My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1257

    1.

    Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.

    Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.

    Breast Cancer Res. 2008;10(3):R46. Epub 2008 May 16.PMID: 18485221 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.

    Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, Frikha M, Jlidi R, Gargouri A, Mokdad-Gargouri R.

    J Cancer Res Clin Oncol. 2010 Feb;136(2):203-10. Epub 2009 Aug 6.PMID: 19657672 [PubMed - indexed for MEDLINE]Related articles

    3.

    Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.

    Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B.

    Clin Cancer Res. 2005 Mar 15;11(6):2156-62.PMID: 15788661 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Correlation between CpG methylation profiles and hormone receptor status in breast cancers.

    Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y.

    Breast Cancer Res. 2007;9(4):R57.PMID: 17764565 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

    Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

    Breast Cancer Res. 2009;11(2):R15. Epub 2009 Mar 9.PMID: 19272155 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

    Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.

    Breast Cancer Res. 2009;11(3):R27. Epub 2009 May 11.PMID: 19432961 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.

    Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.

    Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.PMID: 19256737 [PubMed - indexed for MEDLINE]Related articles

    8.

    Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.

    Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, Henshall SM, Visvader JE, Sutherland RL.

    Int J Cancer. 2010 Mar 15;126(6):1445-53.PMID: 19676041 [PubMed - indexed for MEDLINE]Related articles

    9.

    Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.

    Wilson KS, Roberts H, Leek R, Harris AL, Geradts J.

    Am J Pathol. 2002 Oct;161(4):1171-85.PMID: 12368191 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

    Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

    J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.PMID: 12529347 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    How to target estrogen receptor-negative breast cancer?

    Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M.

    Endocr Relat Cancer. 2003 Jun;10(2):261-6. Review.PMID: 12790787 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.

    Cancer. 2008 Mar 1;112(5):995-1000.PMID: 18098228 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.

    Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S.

    Cancer Sci. 2009 Jun;100(6):1062-8. Epub 2009 Mar 9.PMID: 19385968 [PubMed - indexed for MEDLINE]Related articles

    14.

    FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

    Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.PMID: 17671124 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

    Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.

    J Clin Oncol. 2007 Oct 1;25(28):4423-30.PMID: 17906205 [PubMed - indexed for MEDLINE]Related articles

    16.

    Impact of triple negative phenotype on breast cancer prognosis.

    Kaplan HG, Malmgren JA.

    Breast J. 2008 Sep-Oct;14(5):456-63. Epub 2008 Jul 24.PMID: 18657139 [PubMed - indexed for MEDLINE]Related articles

    17.

    Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.

    Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H, Nishio K, Ono M, Kuwano M, Kage M.

    Cancer Res. 2008 Mar 1;68(5):1504-12.PMID: 18316615 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Do we need HER-2/neu testing for all patients with primary breast carcinoma?

    Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.

    Cancer. 2003 Dec 15;98(12):2547-53.PMID: 14669272 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Association between frequent CpG island methylation and HER2 amplification in human breast cancers.

    Terada K, Okochi-Takada E, Akashi-Tanaka S, Miyamoto K, Taniyama K, Tsuda H, Asada K, Kaminishi M, Ushijima T.

    Carcinogenesis. 2009 Mar;30(3):466-71. Epub 2009 Jan 23.PMID: 19168584 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases]

    Liu RB, Zhou XH, Wang JN, Liang HZ, Li XX, Wu ZH, Ye JL, Wang SM.

    Zhonghua Yi Xue Za Zhi. 2008 Dec 30;88(48):3397-400. Chinese. PMID: 19159568 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk